| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: GXDX |
| Security Type |
Common Stock |
| Lead Underwriter |
Lehman Brothers |
| Days In Registration |
90 |
| Date Filed |
31-Jul-2007 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Healthcare |
| Business Description |
Provide bone marrow and blood evaluation and morphology, flow cytometric phenotyping for hematologic malignancies, circulating tumor call test for metastatic breast cancer and tumor response assessment services for chemoresponse |
| Revenue |
$59.3M |
| Net Income |
$13.4M |
| Shares Outstanding (post-offering) |
15.62M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
5.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$75.0M |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
Current Filing Information
(Amended 18-Oct-2007) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
0.71M |
| · As a Percent |
14.3 |
| Primary Shares Filed |
4.29M |
| · As a Percent |
85.7 |
| Overallotment Shares Filed |
- |
| File Amount |
$75.0M |
| · % Change from Original |
0.0 |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
|
